The comparison of two different direct acting antiviralregimens in treatment of chronic hepatitis C virus

Aim: Chronic hepatitis C virus (HCV) is considered a critical threat to the public health in the world. We compared treatment outcomesof Ombitasvir, Paritaprevir and Ritonavir with Dasabuvir (PrOD) and Ledipasvir (LDV) and Sofosbuvir (SOF) in real world patients with chronic HCV in treatment-naïve and pre-treated patients with chronic HCV.MaterialS and Methods: 91 adult patients enrolled in our study and were divided in two groups. The first group; consisted of 53patients, who orally received a fixed-dose combination tablet comprised of LDV and SOF once daily for 24 weeks. The second group; consisted of 38 patients, who orally received a fixed-dose combination tablet comprised of PrOD twice daily for 12 weeks without regard to fat or calorie content. Results: The results showed that sustained virologic response (SVR) rates were 100% in the both groups analyzed. 76 adverse eventswere occurred in total. 46 of overall adverse events were found on patients in the first group and 30 of those events were found on patients in the second group. Weakness (13.1%), pruritus (5.5%), myalgia (1.1%) nausea (5.5%), dry mouth (1.1%) and insomnia (1.1%) were observed among the patients. Twelve weeks after initiating treatment, virologic suppression was accomplished for all patients in the both groups. Additionally, laboratory analysis concluded that HCV-RNA levels of the overall patients were negative after 48 weeks of the onset of the treatment.Conclusion: The real world comparative analysis of two distinct treatment regimens concluded that administration of PrOD and LDV/ SOF on the patients with chronic HCV has an extremely effective outcome. SVR12 rates of 100% were obtained in both treatment regimens for all treatment naïve and treatment-experienced patients regardless of cirrhosis occurrence and of HCV genotype.

PDF

___

1. World Health Organization: Global Hepatitis Report. https://www.who.int/hepatitis/publications/global-
hepatitis-report2017/en/ access date April 207
2. De Ávila Machado MA, De Moura CS, Klein M, et al.
Direct-Acting Antivirals for Hepatitis C: Predictors of
Early Discontinuation in the Real World. J Manag Care
Spec Pharm 2019;25:697-704.
3. Geddawy A, Ibrahim YF, Elbahie NM, et al. Direct Acting
Anti-hepatitis C Virus Drugs: Clinical Pharmacology
and Future Direction. J Transl Int Med 2017;5:8-17.
4. Indolfi G, Serranti D, Resti M. Direct-acting antivirals
for children and adolescents with chronic hepatitis C.
Lancet Child Adolesc Health 2018;2:298-304.
5. Asselah T, Marcellin P. Direct acting antivirals for the
treatment of chronic hepatitis C: one pill a day for
tomorrow. Liver Int 2012;32:88-102.
6. Loo N, Lawitz E, Alkhouri N, et al. Ombitasvir/
paritaprevir/ritonavir + dasabuvir +/- ribavirin in real
world hepatitis C patients. World J Gastroenterol 2019;25:2229-39.
7. Matthew AN, Zephyr J, Hill CJ, et al. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2
Quinoxalines Target Drug Resistant Viral Variants. J
Med Chem 2017;60:5699-716.
8. Gitto S, Gamal N, Andreone P. NS5A inhibitors for
the treatment of hepatitis C infection. J Viral Hepat
2017;24:180-86.
9. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor
in the treatment of hepatitis C: a review of its clinical
potential. Therap Adv Gastroenterol 2014;7:131-40.
10. Gentile I, A.R. Buonomo, G. Borgia. Dasabuvir: A Non-
Nucleoside Inhibitor of NS5B for the Treatment of
Hepatitis C Virus Infection. Rev Recent Clin Trials
2014;9:115-23.
11. World Health Organization: Guidelines for the care and
treatment of persons diagnosed with chronic hepatitis
C virus infection. https://www.who.int/hepatitis/
publications/hepatitis-c-guidelines-2018/en/ access
date July 2018.
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
sofosbuvir for previously treated HCV genotype 1
infection. N Engl J Med 2014;370:1483-93.
13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and
sofosbuvir for untreated HCV genotype 1 infection. N
Engl J Med 2014;370:1889-98.
14. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir
and sofosbuvir for 8 or 12 weeks for chronic HCV
without cirrhosis. N Engl J Med 2014;370:1879-88.
15. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–
Ombitasvir and Dasabuvir with or without Ribavirin for
HCV. N Engl J Med 2014;370:1983-92.
16. Manuel Sousa J, Vergara M, Pulido F, et al. Real-
world evidence of the effectiveness of ombitasvir-
paritaprevir/r +/- dasabuvir +/- ribavirin in patients
monoinfected with chronic hepatitis C or coinfected
with human immunodeficiency virus-1 in Spain. PLoS
One 2019;14:0225061.
17. Ahmed H, Abushouk AI, Menshawy A, et al. Safety
and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and
Dasabuvir with or without Ribavirin for Treatment of
Hepatitis C Virus Genotype 1: A Systematic Review
and Meta-analysis. Clin Drug Investig 2017;37:1009-
23 .
18. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment
of HCV with ABT-450/r–Ombitasvir and Dasabuvir
with Ribavirin. N Engl J Med 2014;370:1604-14.
19. Kouris G, Hydery T, Greenwood BC, et al. Effectiveness
of Ledipasvir/Sofosbuvir and Predictors of Treatment
Failure in Members with Hepatitis C Genotype 1
Infection: A Retrospective Cohort Study in a Medicaid
Population. J Manag Care Spec Pharm 2018;24:591-
97.
20. Stewart RA, MacDonald BR, Chu T, et al. Ledipasvir/
Sofosbuvir Effectively Treats Hepatitis C Virus
Infections in an Underserved Population. Dig Dis Sci
2018;63:3233-40.
21. Del Rio-Valencia JC, Asensi-Diez R, Tamayo-Bermejo
R, et al. Effectiveness of 12 week ledipasvir/sofosbuvir
and predictors of treatment failure in patients with
hepatitis C. Rev Esp Quimioter 2019;32:296-302.
22. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of
Direct-Acting Antiviral Combination for Patients With
Hepatitis C Virus Genotype 1 Infection and Severe
Renal Impairment or End-Stage Renal Disease.
Gastroenterology 2016;150:1590-8.
23. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir,
paritaprevir co-dosed with ritonavir, dasabuvir, and
ribavirin for hepatitis C in patients co-infected with
HIV-1: a randomized trial. JAMA 2015;313:1223-31. 24. Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir,
paritaprevir, and ritonavir plus dasabuvir for 8 weeks
in previously untreated patients with hepatitis C virus
genotype 1b infection without cirrhosis (GARNET):
a single-arm, open-label, phase 3b trial. Lancet
Gastroenterol Hepatol 2017;2:494-500.
25. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic
response of 100% in HCV genotype 1b patients with
cirrhosis receiving ombitasvir/paritaprevir/r and
dasabuvir for 12 weeks. J Hepatol 2016;64:301-7.
26. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/
paritaprevir/ritonavir and dasabuvir tablets
for hepatitis C virus genotype 1 infection. Ann
Pharmacother 2015;49:566-81.
27. Smith MA, Chan J, Mohammad RA. Ledipasvir-
sofosbuvir: interferon-/ribavirin-free regimen for
chronic hepatitis C virus infection. Ann Pharmacother
2015;49:343-50.
28. Ormeci N, Gulsen MT, Sezgin O, et al. Treatment of
HCV infection with direct-acting antiviral agents.
Real life experiences from Euro-Asian region. Turk J
Gastroenterol 2020;31:148-55.
29. Pawlotsky JM. Hepatitis C virus resistanceto direct-
acting antiviral drugs in interferon-free regimens.
Gastroenterology 2016;151:70-86.
30. Cabalak M, Bal T, Onlen Y, et al. Incidence and
predictors of direct-acting antiviral treatment failure
in Turkish patients with chronic hepatitis C genotype
1b infection. Trop Doct 2020;50:141-6.
31. Zeng H, Li L, Hou Z, et al. Direct-acting Antiviral in
the Treatment of Chronic Hepatitis C: Bonuses and
Challenges. Int J Med Sci 2020;17:892.